Haemonetics Corporation (HAE)

Net profit margin

		Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net income	US$ in thousands	117,558	115,401	43,375	79,469	76,526
Revenue	US$ in thousands	2,594,610	2,323,320	985,896	860,363	972,079
Net profit margin		4.53%	4.97%	4.40%	9.24%	7.87%

March 31, 2024 calculation

Net profit margin = Net income ÷ Revenue
= $117,558K ÷ $2,594,610K
= 4.53%

The net profit margin of Haemonetics Corporation has exhibited some fluctuations over the past five years. In the most recent fiscal year ending March 31, 2024, the net profit margin stood at 4.53%, showing a slight decrease from the previous year's figure of 4.97%. This decline suggests that the company's profitability relative to its revenue has decreased compared to the prior year.

Looking back further, the net profit margin in fiscal year 2022 was 4.40%, indicating a similar level of profitability as in 2024. However, there was a notable drop in profitability in fiscal year 2021, with the net profit margin reaching 9.24%. This was significantly higher compared to the surrounding years, potentially reflecting a period of exceptional profitability or efficiency in cost management.

In fiscal year 2020, the net profit margin was 7.87%, suggesting relatively strong profitability compared to the more recent years but slightly lower compared to the exceptional performance in fiscal year 2021.

Overall, the analysis of Haemonetics Corporation's net profit margin indicates some variability in the company's ability to convert revenue into profit over the past five years. Further investigation into the drivers behind these fluctuations, such as changes in costs, pricing strategies, or revenue mix, could provide valuable insights into the company's financial performance and prospects for future profitability.